Drug intelligence / Profile preview

DWETR25

Development stage: Unknown
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWETR25 is a code name for an investigational drug formulation studied in clinical trials. It appears in the context of a pharmacokinetic study comparing Etravil (a brand of amitriptyline) formulations, specifically DWETR10 and DWETR25, which likely refer to different dosage strengths or formulations of Etravil. The available information does not specify the exact composition or mechanism of action for DWETR25 itself, but it is associated with Dong Wha Pharmaceutical as the developer and sponsor[2].

Beyond the preview

Go deeper on DWETR25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWETR25.

Explore the full profile